Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Schuurhuis, Gerrit J ^a   Meel, Michael H ^a   Wouters, Floris ^a   Min, Lisa A ^a   Terwijn, Monique ^a   De Jonge, Nick A ^a   Kelder, Angele ^a   Snel, Alexander N ^a   Zweegman, Sonja ^a   Ossenkoppele, Gert J ^a   Smit, Linda ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; CD34 ANTIGEN; CD38 ANTIGEN; MOLECULAR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL SUBPOPULATION; CONTROLLED STUDY; ENZYME ACTIVITY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; LEUKEMIA CELL; PROTEIN EXPRESSION;

ALDEHYDE DEHYDROGENASE; ANTIGENS, CD34; ANTIGENS, CD38; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS;

EID: 84893021030     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078897     Document Type: Article

References (40)

1. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737.
2. Lowenberg B, Griffin JD, Tallman MS (2003) Acute myeloid leukemia and acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program 82-101.
3. Van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, et al. (2005) High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 11: 6520-6527.
4. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, et al. (2007) Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotech 11: 1315-1321.
5. Terwijn M, Rutten AP, Kelder A, Snel AN, Scholten WJ, et al. (2010) Accurate detection of residual leukemic stem cells in remission bone marrow predicts relapse in acute myeloid leukemia patients. Blood ASH Annu Meet Abstr 759.
6. Pearce DJ, Taussig D, Zibara K, Smith LL, Ridler CM, et al. (2006) AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 107: 1166-1173.
7. Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, et al. (2011) Stem cell gene expression programs influence clinical outcome in human leukemia. Nature Med 17: 1086-1093.
8. Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, et al. (2010) Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood 115: 1976-1984.
9. Taussig DC, Miraki-Moud F, Anjos-Afononso F, Pearce DJ, Allen K, et al. (2008) Anti-CD38 antibody mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 112; 568-575.
10. Buggins AG, Milojkovic D, Arno MJ, Lea NC, Mufti GJ, et al. (2001) Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways. J Immunol 167: 6021-6030.
11. Feller N, van der Pol MA, van Stijn A, Weijers GW, Westra AH, et al. (2004) MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 18: 1380-1390.
12. van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint AW, et al. (2007) Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 8: 1700-1707.
13. van Rhenen A, van Dongen GA, Kelder A, Rombouts EJ, Feller N, et al. (2007) The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 110: 2659-2666.
14. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, et al. (2000) The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 10: 1777-1784.
15. Bakker AB, van den Oudenrijn S, Bakker AQ, Feller N, van Meijer M, et al. (2004) C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res 64: 8443-8450.
16. Janssen JJ, Deenik W, Smolders KG, van Kuijk BJ, Pouwels W, et al. (2011) Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib. Leukemia Dec 9. doi: 10.1038/leu.2011.347.
17. Chute JP, Muramoto GG, Whitesides J, Colvin M, Safi R, et al. (2006) Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci USA 103: 11707-11712.
18. Duester G (2000) Families of retinoid dehydrogenases regulating vitamin A function: production of visual pigment and retinoic acid. Eur J Biochem 267: 4315-4324.
19. Magni M, Shammah S, Schiró R, Mellado W, Dalla-Favera R, et al. (1996) Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood 87: 1097-1103.
20. Wang JS, Fang Q, Sun DJ, Chen J, Zhou XL, et al. (2001) Genetic modification of hematopoietic progenitor cells for combined resistance to 4-hydroperoxycyclophosphamide, vincristine, and daunorubicin. Acta Pharmacol Sin 10: 949-955.
21. Takebe N, Zhao SC, Adhikari D, Mineishi S, Sadelain M, et al. (2001) Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene. Mol Ther 1: 88-96.
22. Kastan MB, Schlaffer E, Russo JE, Colvin OM, Civin CI, et al. (1990) Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 75: 1947-1950.
23. Armstrong L, Stojkovic M, Dimmick I, Ahmad S, Stojkovic P, et al. (2004) Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem cells 22: 1142-1151.
24. Gentry T, Deibert E, Foster SJ, Haley R, Kurtzberg J, et al. (2007) Isolation of early hematopoietic cells, including megakaryocyte progenitors, in the ALDH-bright cell population of cryopreserved, banked UC blood. Cytotherapy 9: 569-576.
25. Storms RW, Trujillo AP, Springer JB, Shah L, Colvin OM, et al. (1999) Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci USA 96: 9118-9123.
26. Christ O, Lucke K, Imren S, Leung K, Hamilton M, et al. (2007) Improved purification of hematopoietic stem cells based on their elevated aldehyde dehydrogenase activity. Haematologica 92: 1165-11 72.
27. Hess DA, Meyerrose TE, Wirthlin L, Craft TP, Herrbrich PE, et al. (2004) Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 104: 1648-1655.
28. Cheung AM, Wan TS, Leung JC, Chan LY, Huang H, et al. (2007) Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 21: 1423-30.
29. Ran D, Schubert M, Pietsch L, Taubert I, Wuchter P, et al. (2009) Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcome. Exp Hematology 12;1423-1434.
30. van der Pol MA, Feller N, Roseboom M, Moshaver B, Westra G, et al. (2003) Assessment of the normal or leukemic nature of CD34+ cells in acute myeloid leukemia with low percentages of CD34 cells. Haematologica 88: 983-993.
31. Taussig DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, et al. (2005) Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 106: 4086-4092.
32. Dash A, Gilliland DG (2001) Molecular genetics of acute myeloid leukaemia. Best Pract Res Clin Haematol 1: 49-84.
33. Pearce DJ, Taussig D, Simpson C, Allen K, Rohatiner AZ, et al. (2005) Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem cells 23: 752-760.
34. Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, et al. (2012) A clinically relevant population of leukemic CD34+CD38- cells in acute myeloid leukemia. Blood 119: 3571-3577.
35. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, et al. (2007) ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome. Cell Stem Cell 1: 555-567.
36. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, et al. (2009) Aldehyde Dehydrogenase 1 Is a Tumor Stem Cell-Associated Marker in Lung Cancer. Mol Cancer Res 7: 330-338.
37. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, et al. (2009) Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 15: 4234-4241.
38. Wang JC (2010) Good cells gone bad: the cellular origins of cancer. Trends Mol Med 16: 145-151.
39. Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, et al. (2011) Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 19: 138-152.
40. Wang L, Feng Z, Wang X, Wang X, Zhang X (2010) DEGseq: an R package for identifying differentially expressed genes from RNA-seq data. Bioinformatics 26: 136-138.